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Abstract
Background: Epidemiologic studies are reporting associations between lead exposure and human cancers. A polymorphism
in the 5-aminolevulinic acid dehydratase (ALAD) gene affects lead toxicokinetics and may modify the adverse effects of lead.
Methods: The objective of this study was to evaluate single-nucleotide polymorphisms (SNPs) tagging the ALAD region
among renal cancer cases and controls to determine whether genetic variation alters the relationship between lead and
renal cancer. Occupational exposure to lead and risk of cancer was examined in a case-control study of renal cell carcinoma
(RCC). Comprehensive analysis of variation across the ALAD gene was assessed using a tagging SNP approach among 987
cases and 1298 controls. Occupational lead exposure was estimated using questionnaire-based exposure assessment and
expert review. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using logistic regression.
Results: The adjusted risk associated with the ALAD variant rs8177796
CT/TT was increased (OR=1.35, 95%CI=1.05–1.73,
p-value=0.02) when compared to the major allele, regardless of lead exposure. Joint effects of lead and ALAD rs2761016
suggest an increased RCC risk for the homozygous wild-type and heterozygous alleles (
GGOR=2.68, 95%CI=1.17–6.12,
p=0.01;
GAOR=1.79, 95%CI=1.06–3.04 with an interaction approaching significance (pint=0.06).. No significant
modification in RCC risk was observed for the functional variant rs1800435
(K68N). Haplotype analysis identified a region
associated with risk supporting tagging SNP results.
Conclusion: A common genetic variation in ALAD may alter the risk of RCC overall, and among individuals occupationally
exposed to lead. Further work in larger exposed populations is warranted to determine if ALAD modifies RCC risk associated
with lead exposure.
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Introduction
Lead is a naturally occurring heavy metal used in the
manufacturing of consumer products including; batteries, paints,
metal products (such as sheet metal), cable covering, and ceramic
glaze. The wide-spread use of lead in manufacturing results in a
continued occupational exposure to lead world-wide. The toxic
effects of acute lead exposure are well-established. At high levels, lead
exposure results in adverse effects on hematopoietic, gastrointestinal,
urinary, cardiovascular, and nervous systems [1]. At lower doses,
chronic lead exposure has been associated with aberrant cognitive
development in children, anemia, hypertension, and the development
of neurological disorders [2,3,4,5]. The International Agency for
Research on Cancer (IARC) classifies inorganic lead as a probable
human carcinogen (Group 2A), based on sufficient evidence from
animal studies and limited epidemiologic research [6] .
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e20432One of the most important mechanisms of lead toxicity is its
inhibition of key enzymes within the heme biosynthetic pathway.
The most well characterized interaction is between lead and the
second enzyme in the heme biosynthetic pathway known as 5-
aminolevulinic acid dehydratase (ALAD). The gene that encodes
ALAD exists in two polymorphic forms (ALAD1 and ALAD2 [SNP
rs1800435]) that may influence an individual’s susceptibility to
lead poisoning [7]. The difference between the two forms of
ALAD is an amino acid substitution of an asparagine for lysine
residue 59; resulting from a single amino acid change in position
177 of the coding region [8]. This substitution results in an
increased affinity of ALAD2 for lead compared to ALAD1 [9].
Rodents genetically modified to have an extra copy of the ALAD
gene accumulated an average of 2.4-fold higher levels of lead in
the kidney, 4.1-times higher in the liver, and 2.5-fold higher in the
brain compared to those with a single copy exposed to the same
doses [10].
Recently, we reported an increase in renal cell carcinoma
(RCC) risk among participants in the Central Eastern European
Renal Cell Cancer Study occupationally exposed to lead [11]. Due
to the important role of ALAD in lead metabolism, we
hypothesized that common genetic variation in ALAD may alter
lead exposure and be associated with RCC risk. To test this
hypothesis, we comprehensively evaluated 19 single nucleotide
polymorphisms (SNPs) in and around the ALAD gene in this study.
Materials and Methods
Study Population
The Central and Eastern European Renal Cell Cancer Study
(CEERCC) is a hospital based case-control study conducted in
seven centers across 4 Eastern European countries (Moscow,
Russia; Bucharest, Romania; Lodz, Poland; and Prague,
Olomouc, Ceske Budejovice and Brno, Czech Republic) from
August, 1999 to January, 2003. Centers were coordinated
jointly by the US National Cancer Institute (NCI) and IARC.
C a s e sa r ed e f i n e da sp a t i e n t sb e t w e e nt h ea g e so f2 0a n d7 9
years newly diagnosed with histologically confirmed RCC
[ICD-O2; C64, International Classification of Disease for
Oncology, Second Revision [12]]. Information on date and
method of RCC diagnosis, tumor location, and stage and grade
was abstracted from hospital records by trained medical staff.
Controls were selected at each center among subjects admitted
as in-patients or out-patients in the same hospital as the cases,
with non-tobacco-related conditions and were frequency
matched with cases by sex and age (+/2 3y e a r s ) ,a n db ys t u d y
center. Patients with cancer or genitourinary disorders except
for benign prostatic hyperplasia were also excluded from the
controls. Although controls had to be cancer-free at the time of
enrollment, previous history of cancer was not an exclusion
criterion in either cases or controls. No single disease made up
more than 20% of the diseases among selected controls from
each center. Diagnoses of controls included digestive (20.3%),
central nervous system (14.3%), eye and ear (16.9%), and
musculoskeletal/connective tissue diseases (12.1%). Overall,
1097 cases and 1555 controls were interviewed, with response
rates that ranged from 90 to 98.6% across study centers. Face to
face interviews were conducted at each center. Collection of
general demographic and risk factor information has been
previously described [13,14]. Blood samples were collected and
stored at 280uC. Genomic DNA was extracted from whole
blood buffy coat using standard phenol chloroform methods. In
total, DNA was isolated from 987 cases and 1298 controls for
genotyping. Informed consent was obtained from all partici-
pants, and the protocol was approved by the appropriate
institutional review boards at each center.
Genotyping
Genotyping was performed using two different methods:
1. TaqMan (Applied Biosysytems, Foster City, CA) assays were
used to genotype genomic DNA for the SNP rs1800435. This
SNP was chosen based on its functional relevance.
2. To comprehensively evaluate common variation across the
ALAD gene region, GoldenGate (IlluminaH, San Diego, CA)
assays were used to analyze 18 additional SNPs (Table 1). SNP
selection favored those with an expected minor allele frequency
of .0.05 in Caucasians, those previously evaluated in the
ALAD gene, and non-synonymous SNPs with potential
functional relevance.
Table 1 lists all SNPs genotyped using either the TaqManH or
GoldenGate method. SNPs were selected to provide high genomic
coverage acrossALAD. SNPswithminorallelefrequenciesofat least
5% and an r
2 of $.80 within the genomic regions 20 kb 59 of the
start of transcription and 10 kb 39 of the final exon (based on
HapMap CEU data [15] were included. Nonsynonymous SNPs or
those correlated with polymorphisms having potential functional
significance were also included in this analysis. All genotyping was
performed at the Core Genotyping Facility of the Division of
Cancer Epidemiology and Genetics, National Cancer Institute
(Frederick, MD). Detailed methods for all genotyping assays can be
found at http:snp500cancer.nci.nioh.gov [16]. Genotyping was
conducted by lab staff blinded to case/control status. Duplicate
genotyping was performed for a randomly selected 5% of the total
series for quality control purposes. The completion rate for all SNPs
ranged from 98–100%. Concordance was .98% for all SNPs
except rs1693474 [(7758 C.T) concordance=95.51%]. The
genotype frequencies among controls showed no deviation from
the expected Hardy-Weinberg equilibrium proportions (p.0.05).
Lead Exposure Assessment
Exposure was estimated using a thorough questionnaire-based
exposure assessment strategy that has been previously described
[11]. Briefly, face-to-face interviews were performed at each center.
The questionnaire wasadministered bytrained interviewers blinded
to case-control status. Cases and controls were asked about their
lifestyle habits, including such things as smoking and family medical
history. This general questionnaire including a description of the
tasks, machines used, working environment and time spent on each
task was used for each job held at least one year. A second,
specialized occupational questionnaire was administered in cases of
employment in specific jobs or industries likely to entail exposure to
lead. Details on the questionnaires have been previously reported
[17]. For each job held, a team of chemists, industrial hygienists and
occupational physicians evaluated lead exposure. Based on the
general occupational questionnaire, the specialized questionnaires,
and the assessor’s own experience in industrial hygiene and
knowledge about historical working conditions and tasks performed
in the study areas, the frequency, intensity, and confidence of
exposure were estimated [17]. Being ever exposed to lead was
defined as someone who had held a job for more than 1 year at
which they were ever exposed to lead dust or fumes. Frequency and
intensity of lead exposure were not evaluated in this study.
Statistical Analysis
For each SNP, we estimated the odds ratio (OR) and 95%
confidence intervals (95% CI) using unconditional logistic
Lead Exposure, ALAD, and Renal Cell Carcinoma
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performed using STATA version 10.0 (StataCorp, College
Station, TX). Based on findings from previous studies, known or
suspected risk factors for RCC (listed in Table 2) were included in
the regression model individually to determine significance
(p=,0.05). We then used forward selection to add significant
variables to the model. All logistic regression models were adjusted
for gender, age (categorical), and center (Czech Republic is a
combination of 4 separate centers in Brno, Olomouc, Prague and
Ceske). Smoking status, body mass index, self-reported hyperten-
sion, and family history of cancer did not alter the risk estimates by
more than 10%; therefore these variables were not included in the
final model. ORs were analyzed using the major homozygous
allele as the referent group and separately comparing the
heterozygous and homozygous minor alleles to subjects homozy-
gous for the major allele as the referent. When the number of
observations in the heterozygous or homozygous rare allele groups
was less than 5% of the total genotypes among controls, the two
categories were combined and compared to the referent group.
Haplotypes in the candidate block were analyzed using an R
package Haplostats (Version 1.3.1) in (version 2.4.1), adjusting for
gender, age, and center. The most common haplotype was used as
the reference group and rare haplotypes (frequencies of ,2%) were
combined. We applied a haplotype-based sliding window approach
with a fixed window size of 5 consecutive SNPs along the candidate
gene. To test if specific haplotypes were associated withrenal cancer
risk, both a score and likelihood ratio test (LRT) were conducted. A
global test that took into account all constructed haplotypes within a
given haplotype block was conducted using a score test. SNP
rs1800435 (Ex4 +13G.C (K68N)) was excluded from this analysis
due to a high rate of missing data.
Heterogeneity of genotype frequencies between centers was
evaluated by using the LRT. We found little evidence of
heterogeneity across study centers. Moreover, no evidence of
population stratification was apparent from a principal components
analysis of a genome wide association study conducted in this
population [18], and the likelihood of this is small among European
populations [19]. To assess effect modification by risk factors of
interest, we initially stratified the genotype analysis. Analysis to
examine the joint effect of lead and genotype on RCC risk was then
examined by adjusted logistic regression using a common referent
group and an LRT for interaction (p=,0.05 significance).
Results
Genotyping data was available on 987 (84.2%) cases and 1,248
(80.2%) of controls (Table 2). Subjects not genotyped were similar
to those included in this study with respect to age, gender, and
other known RCC risk factors (data not shown). The study
population was of Caucasian descent, mostly male (60%) between
55–74 years of age (63%). Cases tended to be heavier and were
more likely to report a history of hypertension and family history
of cancer than controls. We first explored the association between
lead exposure and RCC risk. After adjusting for age, gender, and
center, the overall risk of RCC was increased among partici-
pants exposed to any lead (OR=1.70, 95%CI=1.21–2.38;
p-value=0.002) when compared to those with no reported lead
exposure (data not shown). Using logistic regression across all
included SNPs, we found little evidence of inter-country ALAD
heterogeneity. In addition, we recently reported no evidence of
lead exposure heterogeneity between countries (OR for exposure
with a p-value=0.12) [11].
Individual SNP and Haplotype Analysis
When the main effects of individual SNPs were analyzed, those
that carried the T allele at SNP rs8177796
CT/TT had a significantly
Table 1. ALAD tagging Single Nucleotide Polymorphisms (SNPs) evaluated in the Central Eastern European Renal Cancer Study.
Chromosome
location
Location of Nucleotide
Change
Amino Acid
Change dbSNP ID
Minor allele frequency
in control population
Assay (Golden Gate
or Taqman)
9q33 g.-22966C.T rs14419 0.36 GoldenGate
g.-19563T.A rs818694 0.30 GoldenGate
9q32 g.IVS1+1425G.C rs818688 0.37 GoldenGate
g.IVS1+2615G.T rs818687 0.18 GoldenGate
g.IVS123185G.A rs2792818 0.17 GoldenGate
g.IVS2+299C.T rs8177796 0.08 GoldenGate
g.IVS32196G.A rs8177800 0.08 GoldenGate
Ex4+13G.C K68N rs1800435 0.08 Taqman
g.IVS42139G.A rs2761016 0.44 GoldenGate
g.Ex6+17C.T N147N rs2228083 0.11 GoldenGate
g.IVS11+66T.C rs1805313 0.38 GoldenGate
g.Ex12+533C.T rs818708 0.44 GoldenGate
g.Ex12+675G.A rs818707 0.10 GoldenGate
g.Ex12+100C.G rs818705 0.18 GoldenGate
g.Ex12+277C.T rs818704 0.13 GoldenGate
g.Ex12+352C.T rs7042485 0.29 GoldenGate
g.6440T.C rs16933168 0.16 GoldenGate
g.7758C.T rs16936474 0.16 GoldenGate
g.8429C.G rs3750526 0.09 GoldenGate
doi:10.1371/journal.pone.0020432.t001
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OR=1.35, 95%CI=1.05–1.73; p-value=0.02 (Table S1). We did
not observe any interaction with age, gender, reported hypertension,
or smoking. No association was observed with the reported
functionally rs1800435
GC/CC (K68N) variant. Based on our ap r i o r i
hypothesis, we evaluated whether ALAD genotypes modified the risk
of RCC associated with lead exposure (Table S1). Exposure to lead
appeared to further increase RCC risk associated with the
rs8177796
CT/TT variant when compared to the common genotype
(OR=1.67, 95%CI=0.58–4.75, p-value=0.34), but the estimates
did not reach statistical significance. Compared to the common
homozygote genotype, risk was elevated to OR=1.15 and
OR=1.31 in individuals carrying the GA and AA genotype,
respectively, who were not exposed to lead. Among those with lead
exposure, the corresponding ORs were 0.59 and 0.29, respectively.
However, none of the ORs reached statistical significance. No other
tagging SNPs studied within the ALAD gene indicated a significant
change in RCC risk when evaluated by lead exposure.
To further evaluate whether ALAD genotypes alter the
relationship between lead and RCC, we modeled the joint effect
of genotype and lead exposure (Table 3). Risk remained elevated
among individuals not exposed to lead with the rs8177796
CT/TT
(OR=1.34, 95%CI=1.00–1.80, p-value=0.06) variant com-
pared to the most common genotype referent. Exposure to lead
further elevated the observed risk of RCC among participants
having the rs8177796
CT/TT variant (OR=2.52, 95%CI=1.0–
6.35, p=0.05), but the interaction was not significant (p-value for
interaction=0.74). For participants with the wild-type G allele at
the tagging SNP rs2761016, we observed an increase in RCC risk
among participants exposed to lead (
GG genotype: OR=2.68,
95%CI=1.17–6.12;
GA genotype: OR=1.79, 95%CI=1.06–
3.04;
AA genotype OR=0.82, 95%CI=0.29–2.35) with an
interaction of borderline significance (p-value for interac-
tion=0.06). No significant alterations in risk were observed for
the other tagging SNPs studied. Interestingly, after consideration
of lead exposure in the joint model, the odds ratio was significantly
elevated among subjects with the functionally relevant SNP
rs1800435 among those with the GG genotype (OR=1.83;
1.14–2.91, p=0.01) but not among subjects with the GC/CC
genotype (OR=1.14; 0.35–3.69, p=0.83); however the interac-
tion was not significant (p-int=0.43). After examination of
correlation (r
2) values between renal ALAD gene tag SNPs in
Haploview, we observed that in our genotyped population SNPs
rs16933168 and rs1693474 were highly correlated (r
2=0.99). This
r
2 value was greater than that observed between tagging SNPs in
HapMap at the time of SNP selection, which ranged from 80–
90% at the time of selection (Figure S1).
An unadjusted sliding window analysis of consecutive SNPs
identified a 5-SNP region with a high level of signal, span-
ning the first 4 introns of the ALAD gene (Figure S1, global p-
value=,0.01). When this region was evaluated in an adjusted
model, several haplotypes were associated with an increased RCC
risk (Table 4). The strongest association was observed with the G-
C-T-G-G- haplotype (OR=1.55; 95%CI: 1.16–2.06, p=,0.01).
This association appears to be driven by the T allele at rs817796
(intron 2), which was significantly associated with increased RCC
risk in the single SNP analysis (Table S1). We did not have
statistical power to evaluate risk stratified by lead utilizing the
haplotype model.
Discussion
In this study, overall lead exposure was associated with an
increased risk of RCC, and this risk was modified by some ALAD
genotypes. The increased risk associated with lead exposure was
highest among subjects that had heterozygous or homozygous
variants of the rs8177796 polymorphism and those with the
common genotype at SNPs rs8177796 and rs2761016. We found a
suggestion of decreased risk among participants with the
rs2761016 homozygous variant who were exposed to lead. In
addition to finding that occupational lead exposure increased
RCC risk, we observed some ALAD variants alone altered cancer
risk, independent of lead exposure. Confirmation of our findings
will require replication in other large sufficiently powered studies
with extensive lead exposure data.
If the risk of RCC is truly increased in individuals with ALAD
polymorphisms, the question of mechanism depends on whether
the association is dependent upon exogenous chemical exposures
Table 2. Demographic characteristics of Subjects Genotyped
in the Central Eastern European Renal Cancer Study.
Characteristic
Total
Cases
N( % )
987
Controls
N( % )
1298
ap-value
-
Center
b,c
Bucharest, Romania
Lodz, Poland
Moscow, Russia
Czech Republic
b
91 (9.2)
81 (8.2)
288 (29.2)
527 (53.4)
132 (10.2)
197 (15.2)
368 (28.4)
601 (46.3) ,0.0001
Sex
Male
Female
589 (59.7)
398 (40.3)
838 (64.6)
460 (35.4) 0.02
Age at Interview
#44
45–54
55–64
65–74
$75
76 (7.7)
253 (25.6)
303 (30.7)
313 (31.7)
42 (4.3)
108 (8.3)
333 (25.7)
405 (31.2)
397 (30.6)
55 (4.2) 0.58
Smoking Status
c, d
Never
Ever
Missing
454 (46.0)
531 (53.8)
2
528 (40.7)
769 (59.2)
1 0.01
Body Mass Index
,25
25–29
$30
186 (18.8)
531 (53.8)
270 (27.4)
321 (24.7)
693 (53.4)
284 (21.9) ,0.0001
Self-reported Hypertension
No
Yes
Missing
539 (54.6)
447 (45.3)
1
800 (61.6)
497 (38.3)
1 0.001
Family history of Cancer
e
No
Yes
654 (66)
333 (34)
932 (72)
366 (28) 0.004
Exposed to Lead
f
Never
Ever
Missing
675(68.4)
71(7.2)
241(24.4)
976(75.1)
63(4.9)
259(20.0) 0.001
ap-value unadjusted.
bFour centers: Brno, Olomuc, Prague, and Ceske.
cTotals do not equal 100% due to rounding.
dNot significant after adjustment for sex, age, and center.
eFirst degree relative with any cancer.
fEver exposed to lead is defined as someone who has held a job for more than 1
year at which they were ever exposed to lead dust or fumes.
doi:10.1371/journal.pone.0020432.t002
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independently of exposure. The ALAD polymorphisms may
encode an enzyme that is less active that the wild type, resulting
in an accumulation of 5-aminolevulinic acid (ALA), a precursor
thought to be genotoxic [[20,21], reviewed in [22]]. However,
ALAD enzymatic activity has been shown to not be significantly
different [23] when comparing SNPs that result in changes in the
translated sequence such as rs1800435 (K68N). It is possible that
the increased risk of RCC in ALAD genotypic variants observed is
due in part to exogenous chemicals that alter the heme synthesis
pathway. Inhibition of ALAD enzymatic activity has been
reported for multiple chemicals, including trichloroethylene,
bromobenzene, styrene, and lead [24]. Polymorphic differences
for enzyme inhibition have been most notably studied for lead.
Individuals with the polymorphism at position 177 leading to a
GRC transversion (rs1800435) results in three isozymes with
different affinities for lead binding [8,25]. The homozygous
variant has a higher binding affinity for lead and has been
associated with increased blood lead levels [8,25,26,27]. The
biological relevance of this alteration in lead binding is currently
being debated in the literature. Studies have suggested that carriers
of the G177C polymorphism are more susceptible to lead toxicity
[7,8]. Other studies suggest that the enhanced ability for the
ALAD isozyme to bind lead actually confers a protective effect by
sequestering circulating lead, slowing its accumulation in the bone
marrow [28]. In this study, we observed a decrease in risk among
Table 3. Odds ratio (OR) and 95% confidence intervals (CI) for joint ALAD tagging SNP genotypes, occupational lead exposure and
renal cancer risk.
No Lead Exposure Lead Exposure
SNP Cases/Controls
aOR 95% CI p-value
ba OR 95% CI p-value
bc p-int
rs818687 IVS1+2615G.T
GG 495/678 1.0 Referent 1.43 0.87, 2.36 0.16
GT/TT 278/353 1.13 0.89, 1.45 0.31 2.05 1.06, 3.96 0.03 0.43
rs2792818 IVS1+1425G.A
GG 527/698 1.0 1.59 0.91, 2.07 0.05
GA/AA 247/337 1.0 0.78, 1.29 0.98 1.48 0.69, 3.17 0.31 0.65
rs8177796 IVS2+299C.T
CC 624/872 1.0 1.51 0.97, 2.34 0.07
CT/TT 153/161 1.34 1.00, 1.80 0.06 2.52 1.0, 6.35 0.05 0.74
rs8177800 IVS3-196G.A
GG 647/865 1.0 1.41 0.92, 2.19 0.12
GA/AA 130/167 0.86 0.63, 1.18 0.36 2.19 0.84, 5.72 0.11 0.17
rs1800435 Ex4+13G.C (K68N)
GG 642/822 1 1.83 1.14, 2.91 0.01
GC/CC 107/140 1.03 0.73, 1.46 0.87 1.14 0.35, 3.69 0.83 0.43
rs2761016 IVS4-139G.A
GG 216/318 1.0 2.68 1.17, 6.12 0.01
GA 403/523 1.15 0.88, 1.50 0.30 1.79 1.06, 3.04 0.05
AA 158/191 1.31 0.94, 1.84 0.10 0.82 0.29, 2.35 0.68 0.06
rs2228083 (Ex6+17C.T, N147N)
CC 612/815 1.0 1.44 0.92, 2.24 0.11
CT/TT 165/217 1.03 0.77, 1.37 0.84 2.28 0.94, 5.51 0.07 0.46
aOdds ratios, 95% CI and.
bp-values were calculated from conventional logistic regression models adjusted for age, sex, and center.
cTests for interaction for genotypes and lead exposure were calculated using a likelihood ratio test adjusting for age, sex, and region.
doi:10.1371/journal.pone.0020432.t003
Table 4. ALAD Haplotype Association and Renal Cancer Risk.
Haplotype Cases (%) Controls (%) OR
a 95%CI
Adjusted
p-value
Region 1 (chr9:13284-5759)
G-G-C-G-A 29.1 33.0 1
G-G-C-G-G 23.0 21.6 1.21 0.97, 1.49 0.08
G-G-C-A-A 7.8 8.0 1.13 0.85, 1.49 0.38
G-C-C-G-A 7.2 6.8 1.23 0.88, 1.70 0.21
G-C-C-G-G 1.8 4.0 0.53 0.30, 0.93 0.03
G-C-T-G-G 8.1 5.9 1.55 1.16, 2.06 0.002
T-G-C-G-A 8.8 7.6 1.28 0.94, 1.74 0.11
T-G-C-G-G 10.8 10.6 1.15 0.89, 1.47 0.27
brare 3.5 2.5 1.50 0.95, 2.36 0.08
aAdjusted for age, sex, and center.
bRare haplotypes (,2%) were combined into one category.
SNP’s included in haplotype region 1: rs818687 (IVS1+2615G.T), rs2792818
(IVS1+1425G.C), rs8177796 (IVS2+299C.T), rs8177800 (IVS32196G.A),
rs2761016 (IVS42139A.G).
doi:10.1371/journal.pone.0020432.t004
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(K68N)
compared to the wildtype G allele, however the number of cases
did not provide a stable estimate.
The observation that individuals with the rs8177796 homozy-
gous minor allele have an increased risk of RCC independently of
lead exposure may be due to alterations in transcription. The SNP
lies within an intronic region; however it is plausible that the
polymorphism alters transcription of the wild-type ALAD, resulting
in translation of a less active ALAD isozyme. It is also possible that
the risk associated with the rs8177796 wild type variant does not
represent a change in ALAD, but instead is in high linkage
equilibrium with a biologically significant polymorphism that was
captured by our tag SNP, but was not part of our examination. In
contrast, we observed a decrease in RCC risk and significant
interaction with lead exposure for the rs2761016 polymorphism.
Similar to rs8177796, this intronic SNP may be altering ALAD
activity, or could simply be tagging a region harboring an
unidentified polymorphism. Additional genotyping to identify
functional variants and in vitro analysis are needed to further
explore the impact these intronic polymorphisms on ALAD
activity.
The question of renal cancer risk associated with ALAD
genotype has not been previously addressed in the literature.
Recent work on ALAD polymorphsims and risk of brain tumors
suggests an increased risk for meningioma among participants
with the ALAD G177C homozygous genotype [29]. Schober et
al. reported an increased risk of all cause, cardiovascular, and
cancer mortality [30] associated with blood lead levels as low as
5–9 ug/dL [30]; however this study did not analyze the role of
the ALAD genotype. We did not observe a significant change in
RCC risk among participants with the G177C major allele
overall or among lead exposed subjects. This variant was quite
rare in this population and the number of overall cases exposed
to lead was small, there-by under powering this gene-exposure
interaction analysis. We chose to evaluate polymorphisms in
ALAD based on the ap r i o r ibiological and functional consider-
ations, not by screening a large number of associations.
Nonetheless, the possibility that our findings are due to chance
cannot be ruled out. The results should be considered as
hypothesis generating and require confirmation by replication
in other studies.
A limitation of a hospital-based case-control study of occupa-
tional exposures is that the distribution of exposed participants
might not be representative of the underlying healthy population.
We attempted to address this issue by recruiting controls with a
wide range of disease diagnoses. Apart from the neurological
conditions, diseases reported among controls in our study are not
known to be associated with lead exposure. It is thought that
hospitalized patients may have different smoking patterns
compared to the general population. A recent meta analysis
reported the association between smoking and RCC risk is weakest
among hospital-based studies [31]. We attempted to control for
possible selection bias by excluding controls with smoking-related
diseases, however the high number of smokers among our control
population may indicate a bias in our study. Given multiple
centers and countries were used in our study, the potential for
population stratification exists; however we found no evidence of
heterogeneity. It is possible that population stratification remains,
but this is unlikely in European populations [19]. The lack of
environmental measurements of lead exposure is an additional
limitation of our study, which relied upon retrospective recall by
study participants regarding their work history and other risk
factors. However, since both cases and controls were hospitalized
patients, any bias in recall would likely be non-differential with
respect to exposure, attenuating the observed risk. Residual
confounding by environmental lead exposure is also a limitation.
Exposure misclassification is a concern in studies based on
retrospective assessment, potentially causing us to underestimate
risk if it is non-differential between cases and controls. Finally, the
small number of cases exposed to lead and carrying any one ALAD
variant restricts the statistical power of our analysis.
The strengths of this study are the high participation rates thus
minimizing the potential for selection bias. The large sample size
provided sufficient statistical power to evaluate small associations
between genotype (with a prevalence of at least 10%) and risk.
However, due to the low exposure prevalence (,6%), our power
to detect gene-exposure interactions was limited. Our use of job-
specific questionnaire models to collect individual, detailed
exposure information and local, expert-based exposure assess-
ments to evaluate exposure histories is considered a superior
approach for retrospective assessment of occupational exposures in
community-based studies [32]. Although we had limited power
for evaluating risk with respect to lead exposure and ALAD
homozygous minor alleles (particularly those SNPs with suggested
functional relevance), this study is one of the largest case-control
studies of RCC and occupational lead exposure to date. In
addition to the small percentage of RCC can be explained by
familial syndromes including von Hippel-Lindau and hereditary
papillary renal carcinoma roughly 50% of RCC incidence is
thought to be associated with obesity, hypertension, and smoking
[33]. The cause of the remaining half of incident cases remains
unknown. Therefore, this study was designed to assess occupa-
tional and genetic factors in relation to RCC risk in a region with
the highest incident rates worldwide [34]. To clarify the role of
lead in the observed relationship between ALAD variants and risk
of RCC, it will be important to conduct detailed, lead exposure
assessments to evaluate how lead exposure; in combination with
ALAD genetic variants could alter cancer risk in other study
populations.
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